Common non-invasive screening methods like the fecal occult blood test (FOBT) have low sensitivity and specificity for early-stage CRC10 while established serum tumor biomarkers like carcinoembryonic antigen (CEA) and carbohydrate antigen 19−9 (CA 19−9) lack adequate sensitivity and specificity for definitive CRC diagnosis due to their presence in other malignancies11–13. This evidence concerns the gene CEACAM5 and colorectal carcinoma.